G Maschmeyer

Summary

Affiliation: Klinikum Ernst von Bergmann
Country: Germany

Publications

  1. ncbi request reprint New antifungal agents-treatment standards are beginning to grow old
    Georg Maschmeyer
    Charite University Hospital, Campus Virchow Klinikum, Department of Haematology and Oncology, Augustenburger Platz 1, D 13353 Berlin, Germany
    J Antimicrob Chemother 49:239-41. 2002
  2. ncbi request reprint Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients
    Georg Maschmeyer
    Department of Internal Medicine, Hematology and Oncology, Klinikum Ernst von Bergmann, Potsdam, Germany
    Drugs 67:1567-601. 2007
  3. ncbi request reprint New immunosuppressive agents and risk for invasive fungal infections
    Georg Maschmeyer
    Department of Hematology, Oncology, and Palliative Care, Klinikum Ernst von Bergmann, Charlottenstrasse 72, D 14467 Potsdam, Germany
    Curr Infect Dis Rep 11:435-8. 2009
  4. doi request reprint A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012
    Georg Maschmeyer
    Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikum Ernst von Bergmann gGmbH, Charlottenstrasse 72, 14467, Potsdam, Germany
    J Cancer Res Clin Oncol 141:1639-44. 2015
  5. pmc Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
    G Maschmeyer
    Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany
    Ann Oncol 26:21-33. 2015
  6. pmc Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
    Katrin Oertel
    Department of Otorhinolaryngology, Jena University Hospital, Lessingstrasse 2, Jena, D 07740, Germany
    BMC Cancer 12:483. 2012
  7. doi request reprint Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study
    G Maschmeyer
    Klinikum Ernst von Bergmann, Charlottenstrasse 72, 14467 Potsdam, Germany
    Eur J Clin Microbiol Infect Dis 32:679-89. 2013
  8. pmc Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature
    M Sandherr
    Hematology and Oncology Specialized Practice, Weilheim, Germany
    Eur J Med Res 16:139-44. 2011
  9. ncbi request reprint Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections
    Georg Maschmeyer
    Klinikum Ernst von Bergmann, Department of Hematology and Oncology, Potsdam, Germany
    Future Microbiol 1:365-85. 2006
  10. ncbi request reprint [Update on therapy of invasive mycoses in hematology and oncology]
    G Maschmeyer
    Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Potsdam
    Dtsch Med Wochenschr 130:1381-4. 2005

Collaborators

Detail Information

Publications50

  1. ncbi request reprint New antifungal agents-treatment standards are beginning to grow old
    Georg Maschmeyer
    Charite University Hospital, Campus Virchow Klinikum, Department of Haematology and Oncology, Augustenburger Platz 1, D 13353 Berlin, Germany
    J Antimicrob Chemother 49:239-41. 2002
  2. ncbi request reprint Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients
    Georg Maschmeyer
    Department of Internal Medicine, Hematology and Oncology, Klinikum Ernst von Bergmann, Potsdam, Germany
    Drugs 67:1567-601. 2007
    ..Voriconazole prophylaxis may be suitable for prevention of IA as well; however, the results of large clinical trials are still awaited...
  3. ncbi request reprint New immunosuppressive agents and risk for invasive fungal infections
    Georg Maschmeyer
    Department of Hematology, Oncology, and Palliative Care, Klinikum Ernst von Bergmann, Charlottenstrasse 72, D 14467 Potsdam, Germany
    Curr Infect Dis Rep 11:435-8. 2009
    ..Generally, invasive infections are more frequent among these groups and thus are important considerations in the management of patients receiving these immunosuppressive drugs...
  4. doi request reprint A retrospective review of diagnosis and treatment modalities of neuroendocrine tumors (excluding primary lung cancer) in 10 oncological institutions of the East German Study Group of Hematology and Oncology (OSHO), 2010-2012
    Georg Maschmeyer
    Klinik für Hämatologie, Onkologie und Palliativmedizin, Klinikum Ernst von Bergmann gGmbH, Charlottenstrasse 72, 14467, Potsdam, Germany
    J Cancer Res Clin Oncol 141:1639-44. 2015
    ..We sought to document the incidence and treatment modalities in patients with NET/NEC within a period of 2 years...
  5. pmc Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients (allogeneic SCT excluded): updated guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
    G Maschmeyer
    Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam, Germany
    Ann Oncol 26:21-33. 2015
    ..In a considerable number of patients, clinical outcome may be favorable despite respiratory failure, so that intensive care should be unrestrictedly provided in patients whose prognosis is not desperate due to other reasons...
  6. pmc Phase I trial of split-dose induction docetaxel, cisplatin, and 5-fluorouracil (TPF) chemotherapy followed by curative surgery combined with postoperative radiotherapy in patients with locally advanced oral and oropharyngeal squamous cell cancer (TISOC-1)
    Katrin Oertel
    Department of Otorhinolaryngology, Jena University Hospital, Lessingstrasse 2, Jena, D 07740, Germany
    BMC Cancer 12:483. 2012
    ..This phase I study was designed to investigate the safety and tolerability of a split-dose TPF ICT regimen prior to surgery for locally advanced resectable oral and oropharyngeal cancer...
  7. doi request reprint Immediate versus deferred empirical antifungal (IDEA) therapy in high-risk patients with febrile neutropenia: a randomized, double-blind, placebo-controlled, multicenter study
    G Maschmeyer
    Klinikum Ernst von Bergmann, Charlottenstrasse 72, 14467 Potsdam, Germany
    Eur J Clin Microbiol Infect Dis 32:679-89. 2013
    ..While immediate empirical therapy with voriconazole appears to be safe in febrile neutropenic high-risk patients, it was not associated with a significant reduction in IFIs compared with therapy deferred for 96 h after fever onset...
  8. pmc Pharmacology and metabolism of voriconazole and Posaconazole in the treatment of invasive aspergillosis: review of the literature
    M Sandherr
    Hematology and Oncology Specialized Practice, Weilheim, Germany
    Eur J Med Res 16:139-44. 2011
    ..This review will address pharmacological characteristics of the two broad-spectrum antifungal azoles, voriconazole and Posaconazole, which are important for their proper use in clinical practice...
  9. ncbi request reprint Voriconazole: a broad spectrum triazole for the treatment of serious and invasive fungal infections
    Georg Maschmeyer
    Klinikum Ernst von Bergmann, Department of Hematology and Oncology, Potsdam, Germany
    Future Microbiol 1:365-85. 2006
    ..Voriconazole is generally well tolerated with transient visual disturbances, liver enzyme abnormalities and skin rashes being the most common adverse events reported, but these rarely lead to treatment discontinuation...
  10. ncbi request reprint [Update on therapy of invasive mycoses in hematology and oncology]
    G Maschmeyer
    Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Potsdam
    Dtsch Med Wochenschr 130:1381-4. 2005
  11. ncbi request reprint Pharmacological properties and clinical efficacy of a recently licensed systemic antifungal, caspofungin
    Georg Maschmeyer
    Abt Hämatologie und Onkologie, Medizinische Klinik, Klinikum Ernst von Bergmann, Potsdam, Germany
    Mycoses 48:227-34. 2005
    ..Thus, caspofungin represents an interesting and clinically valuable new antifungal drug that broadens the available therapeutic armamentarium for the treatment of invasive fungal infections...
  12. ncbi request reprint Empirical antimicrobial monotherapy in patients after high-dose chemotherapy and autologous stem cell transplantation: a randomised, multicentre trial
    Gernot Reich
    Department of Haematology, Oncology and Tumour Immunology, Charite University Hospital, Campus Buch, Lindenberger Weg, Berlin, Germany
    Br J Haematol 130:265-70. 2005
    ..One patient (0.4%) died from infection. Empirical first-line therapy with MPM as well as with P/T is safe and effective in febrile episodes emerging after ASCT. Higher response rates to primary treatment can be achieved with MPM...
  13. ncbi request reprint [Pulmonary hypertension in sickle cell disease--epidemiology, pathogenesis, diagnosis and treatment]
    G Maschmeyer
    Klinikum Ernst von Bergmann, Medizinische Klinik, Abteilung Hämatologie und Onkologie, Potsdam
    Dtsch Med Wochenschr 132:103-7. 2007
  14. ncbi request reprint The epidemiology and treatment of infections in cancer patients
    Georg Maschmeyer
    Klinikum Ernst von Bergmann, Department of Hematology and Oncology, Charlottenstrasse 72, D 14467 Potsdam, Germany
    Int J Antimicrob Agents 31:193-7. 2008
    ..coli. In patients given moxifloxacin for infection prevention, unacceptably large numbers of Clostridium difficile-associated enterocolitis have been reported...
  15. doi request reprint [Infections in hematology and oncology. Epidemiology--diagnosis--risk-adapted antimicrobial treatment--prevention]
    G Maschmeyer
    Klinik für Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Charlottenstrasse 72, 14467, Potsdam, Deutschland
    Internist (Berl) 50:187-99; quiz 200-1. 2009
    ..Recommendations for prevention, including vaccination, should be known and followed for hospitalized as well as for out-patients...
  16. doi request reprint The changing face of febrile neutropenia-from monotherapy to moulds to mucositis. Prevention of mould infections
    Georg Maschmeyer
    Department of Haematology and Oncology, Klinikum Ernst von Bergmann, Potsdam 14467, Germany
    J Antimicrob Chemother 63:i27-30. 2009
    ....
  17. doi request reprint Invasive mould infections: a multi-disciplinary update
    Georg Maschmeyer
    Department of Haematology and Oncology, Center for Haematology, Oncology and Radiotherapy, Klinikum Ernst von Bergmann, Potsdam, Germany
    Med Mycol 47:571-83. 2009
    ..The challenge is to identify ways of coupling potentially effective treatments with early and reliable identification of patients at highest risk of infection...
  18. doi request reprint Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology
    Georg Maschmeyer
    Klinikum Ernst von Bergmann, Dept of Haematology and Oncology, Charlottenstrasse 72, Potsdam D 14467, Germany
    Eur J Cancer 45:2462-72. 2009
    ..Microbial isolates from blood cultures, bronchoalveolar lavage or respiratory secretions must be critically interpreted with respect to their aetiological relevance for pulmonary infiltrates...
  19. ncbi request reprint [Infectious complications as a consequence of treatment with nucleoside analogs and monoclonal antibodies]
    G Maschmeyer
    Medizinische Klinik, Abt Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Potsdam
    Dtsch Med Wochenschr 131:2414-9. 2006
  20. doi request reprint Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic cancer patients
    Georg Maschmeyer
    Department of Hematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Charlottenstrasse 72, 14467, Potsdam, Germany
    Curr Infect Dis Rep 13:510-6. 2011
    ..Primary choice for treatment of Pneumocystis pneumonia remains high-dose trimethoprim-sulfamethoxazole, while cytomegalovirus pneumonia is treated with ganciclovir in the majority of patients affected...
  21. ncbi request reprint The changing epidemiology of invasive fungal infections: new threats
    Georg Maschmeyer
    Department of Hematology and Oncology, Klinikum Ernst von Bergmann, Potsdam, Germany
    Int J Antimicrob Agents 27:3-6. 2006
    ..It is therefore important to recognize and minimize the major risk factors associated with infection. This paper summarizes the key epidemiological data...
  22. ncbi request reprint Infectious complications after high-dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumors
    G Reich
    , Campus Berlin-Buch, , Department of Hematology, Oncology and Tumor Immunology, Humboldt University of Berlin, Germany
    Bone Marrow Transplant 27:525-9. 2001
    ..6% of patients with documented infections. With respect to the incidence, type and clinical course of infection, no significant differences between patients with lymphoma or multiple myeloma and those with solid tumors were detected...
  23. doi request reprint Diagnosis of invasive fungal infections in hematology and oncology--guidelines from the Infectious Diseases Working Party in Haematology and Oncology of the German Society for Haematology and Oncology (AGIHO)
    M Ruhnke
    Department of Internal Medicine, Charite University Medicine, Campus Charite Mitte, Berlin, Germany
    Ann Oncol 23:823-33. 2012
    ..The AGIHO presents recommendations for the diagnosis of IFIs with risk-adapted screening concepts for febrile episodes in patients with haemato-oncological disorders...
  24. doi request reprint A prospective, randomised study on the use of well-fitting masks for prevention of invasive aspergillosis in high-risk patients
    G Maschmeyer
    Department of Haematology and Oncology, Ernst von Bergmann Clinic, Potsdam
    Ann Oncol 20:1560-4. 2009
    ..Of patients in the mask group, 65% described the comfort as acceptable, 26% as unpleasant, and 9% as intolerable. This first randomised study on the use of well-fitting masks failed to show a reduction of invasive fungal infections...
  25. ncbi request reprint Update on antifungal treatment of invasive Candida and Aspergillus infections
    G Maschmeyer
    Department of Hematology and Oncology, Campus Virchow Klinikum, Charite University Hospital, Humboldt University, Berlin, Germany
    Mycoses 47:263-76. 2004
    ..The selection of systemic antifungals in patients with invasive Candida infection critically depends upon the identification of Candida species involved, because some non-albicans Candida spp. are resistant to azole antifungals...
  26. pmc Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (D
    S Neumann
    Department of Hematology and Oncology, Georg August University Gottingen, Robert Koch Str 40, 37075, Gottingen, Germany
    Ann Hematol 92:433-42. 2013
    ..Risk factors, choice of drug for antibacterial and PCP prophylaxis and concerns regarding the use of prophylactic antibiotics are discussed in the review...
  27. ncbi request reprint [Prolonged remission after immunotherapy of a previously refractory peripheral T-cell non-Hodgkin lymphoma]
    A Haas
    Abteilung Hämatologie und Onkologie, Medizinische Klinik, Klinikum Ernst von Bergmann Potsdam
    Dtsch Med Wochenschr 131:2386-9. 2006
    ..A 54-year-old woman in good condition was admitted because of a rapidly growing tumor in the right groin with skin infiltration. There were no B-symptoms and no increased susceptibility to infections...
  28. ncbi request reprint Four patients with AL amyloidosis treated with high-dose chemotherapy and autologous stem cell transplantation
    G Reich
    , Department of Haematology, Oncology and Tumour Immunology, Humboldt University of Berlin, Germany
    Bone Marrow Transplant 27:341-3. 2001
    ..However, in the other two patients, one of whom was suffering from amyloid-related cardiac failure, a significant improvement of organ function was achieved...
  29. ncbi request reprint Changing patterns of infections and antimicrobial susceptibilities
    G Maschmeyer
    Charite University Hospital, Robert Roessle Cancer Center Hematology, Oncology and Tumor Immunology, Berlin, Germany
    Oncology (Williston Park) 14:9-16. 2000
    ..New drugs or drug combinations will be necessary to treat drug-resistant infections in cancer patients...
  30. pmc CNS infections in patients with hematological disorders (including allogeneic stem-cell transplantation)-Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO)
    M Schmidt-Hieber
    Department of Hematology, Oncology and Tumor Immunology, HELIOS Clinic Berlin Buch, Berlin
    Ann Oncol 27:1207-25. 2016
    ..Grades of recommendation and levels of evidence were categorized by using novel criteria, as recently published by the European Society of Clinical Microbiology and Infectious Diseases. ..
  31. ncbi request reprint Review of the incidence and prognosis of Pseudomonas aeruginosa infections in cancer patients in the 1990s
    G Maschmeyer
    Charite University Hospital, Robert Roessle Cancer Center, Berlin, Germany
    Eur J Clin Microbiol Infect Dis 19:915-25. 2000
    ....
  32. ncbi request reprint Pneumonia in febrile neutropenic patients: radiologic diagnosis
    G Maschmeyer
    Charite University Hospital, Robert Roessle Cancer Center, Humboldt University of Berlin, Berlin, Germany
    Curr Opin Oncol 13:229-35. 2001
    ....
  33. doi request reprint Central venous catheter-related infections in hematology and oncology: 2012 updated guidelines on diagnosis, management and prevention by the Infectious Diseases Working Party of the German Society of Hematology and Medical Oncology
    M Hentrich
    Department of Hematology, Oncology and Palliative Care, Harlaching Hospital and Neuperlach Hospital, Munich
    Ann Oncol 25:936-47. 2014
    ..Cancer patients are at increased risk for central venous catheter-related infections (CRIs). Thus, a comprehensive, practical and evidence-based guideline on CRI in patients with malignancies is warranted...
  34. ncbi request reprint Subgroup specific therapy effects in AML: AMLCG data
    Th Büchner
    German AMLCG, Department of Medicine, Hematology and Oncology, University of Munster, Germany
    Ann Hematol 83:S100-1. 2004
  35. ncbi request reprint Outcome analysis of 189 consecutive cancer patients referred to the intensive care unit as emergencies during a 2-year period
    G Maschmeyer
    Charite University Hospital, Campus Virchow Klinikum, Department of Hematology and Oncology, Humboldt University of Berlin, Germany
    Eur J Cancer 39:783-92. 2003
    ..Cancer patients should not be excluded from referral to the intensive care unit in an emergency solely due to their underlying malignant disease or a single unfavourable prognostic factor...
  36. ncbi request reprint Update on management of infections in cancer and stem cell transplant patients
    Stefan Neuburger
    Department of Hematology and Oncology, Charite University Hospital, Campus Virchow Klinikum, Augustenburger Platz 1, 13353 Berlin, Germany
    Ann Hematol 85:345-56. 2006
    ..The prompt preemptive use of ganciclovir or foscarnet in allogeneic stem cell transplant recipients can reliably be guided by serial monitoring of cytomegalovirus antigen and polymerase chain reaction monitoring...
  37. doi request reprint [Antibiotic therapy in pregnancy]
    A Haas
    Medizinische Klinik, Abt Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Potsdam
    Dtsch Med Wochenschr 133:511-5. 2008
    ..Tetracyclins may only be used before the 12 (th) week of gestation. Quinolones should be strictly avoided due to potential toxicity for the unborn children...
  38. ncbi request reprint Acute myeloid leukemia: treatment over 60
    Thomas Buchner
    University of Munster, Department of Medicine, Hematology and Oncology, Germany
    Rev Clin Exp Hematol 6:46-59; discussion 86-7. 2002
    ..This finding did not vary by age, under or over 60 years. As the median age in this disease is more than 60 years, the adequate management of AML in older patients remains the major challenge...
  39. ncbi request reprint Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Georg Maschmeyer
    Dept of Hematology and Oncology, Charite University Hospital, Campus Virchow Klinikum, Augustenburger Platz 1, 13353, Berlin, Germany
    Ann Hematol 82:S118-26. 2003
    ....
  40. ncbi request reprint Infectious complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Hermann Einsele
    Dept of Hematology, Oncology, Medical Clinic II, University of Tubingen, Otfried Muller Strasse 10, 72076, Tubingen, Germany
    Ann Hematol 82:S175-85. 2003
    ..Infection-associated mortality, for example, is significantly higher following engraftment than during the short neutropenic period that immediately follows transplantation...
  41. ncbi request reprint Prophylaxis of invasive fungal infections in patients with hematological malignancies and solid tumors--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität zu Köln, 50931, Koln, Germany
    Ann Hematol 82:S186-200. 2003
    ..The objective of this review accumulating information on about 10.000 patients is to assess evidence based criteria primarily regarding the efficacy of antifungal prophylaxis in neutropenic cancer patients...
  42. ncbi request reprint Clinical pharmacology of antifungal compounds
    Andreas H Groll
    Infectious Disease Research Program, Center for Bone Marrow Transplantation, Department of Pediatric Hematology Oncology, Wilhelms University Medical Center, Domagkstrasse 9a, 48149 Muenster, Germany
    Infect Dis Clin North Am 17:159-91, ix. 2003
    ....
  43. ncbi request reprint Efficacy of caspofungin against invasive Candida or invasive Aspergillus infections in neutropenic patients
    Robert Betts
    Department of Infectious Diseases, University of Rochester, Rochester, New York, USA
    Cancer 106:466-73. 2006
    ..All available clinical trial experience from the caspofungin development program was reviewed to ascertain the efficacy of caspofungin in neutropenic patients with documented invasive aspergillosis (IA) or invasive candidiasis (IC)...
  44. ncbi request reprint Diagnosis of IPA in HIV: the role of the chest X-ray and radiologist
    Uta Zaspel
    Institut fur Radiologie, Charite Universitatsmedizin Berlin, Campus Mitte, Schuhmannstr 20 21, 10117 Berlin, Germany
    Eur Radiol 14:2030-7. 2004
    ..For internists with regular exposure to HIV patients, chest films do not provide information essential for the verification or differentiation of potential IPA...
  45. ncbi request reprint CD52 is not a promising immunotherapy target for most patients with multiple myeloma
    Jörg Westermann
    Department of Hematology and Oncology, Charite University Medicine Berlin, Campus Virchow Klinikum, Berlin, Germany
    Int J Hematol 82:248-50. 2005
    ..We conclude that CD52 is not a promising target for antibody-based therapies for most patients with multiple myeloma...
  46. doi request reprint Risk factors for breakthrough invasive fungal infection during secondary prophylaxis
    Oliver A Cornely
    Klinik I fur Innere Medizin, Klinikum der Universität Köln, 50924 Köln, Germany
    J Antimicrob Chemother 61:939-46. 2008
    ..This study determines risk factors for recurrent IFI in leukaemia patients...
  47. ncbi request reprint Treatment of fungal infections in hematology and oncology--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Angelika Böhme
    Medizinische Klinik III, J W Goethe Universitat, Theodor Stern Kai 7, 60590, Frankfurt Main, Germany
    Ann Hematol 82:S133-40. 2003
    ..These guidelines offer actual standards and discussions on the treatment of oropharyngeal and esophageal candidiasis, invasive candidiasis, cryptococcosis and mould infections...
  48. pmc Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) C
    Ben de Pauw
    Department of Blood Transfusion Service and Transplant Immunology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Infect Dis 46:1813-21. 2008
    ..Clarity and uniformity in defining these infections are important factors in improving the quality of clinical studies. A standard set of definitions strengthens the consistency and reproducibility of such studies...
  49. doi request reprint Central venous catheter-related infections in hematology and oncology : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Hans Heinrich Wolf
    Klinik für Innere Medizin IV, Onkologie, Hämatologie und Hämostaseologie, Martin Luther Universität Halle, Ernst Grube Str 40, 06120 Halle, Germany
    Ann Hematol 87:863-76. 2008
    ..aureus and Candida infections, as well as in case of tunnel or pocket infections. Future studies will elucidate whether the rate of CRI in neutropenic patients may be reduced by catheters impregnated with antimicrobial agents...
  50. ncbi request reprint Antimicrobial therapy of febrile complications after high-dose chemo-/radiotherapy and autologous hematopoietic stem cell transplantation--guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO)
    Hartmut Bertz
    Dept of Hematology and Oncology, University of Freiburg Medical Center Albert Ludwigs University Freiburg, Hugstetterstrasse 55, 79106, Freiburg, Germany
    Ann Hematol 82:S167-74. 2003
    ..Recombinant hematopoietic growth factors should not be added routinely but may be considered in life-threatening situations such as invasive pulmonary mycoses or sepsis...